skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Comparison of enzyme-linked immunosorbent assay and radioimmunoassay for prostate-specific acid phosphatase in prostatic disease

Journal Article · · Clin. Chem. (Winston-Salem, N.C.); (United States)
OSTI ID:5545324

Results of an enzyme-linked immunosorbent assay (ELISA) are compared with those of a standard radioimmunoassay (RIA) for detection and quantitation of prostate-specific acid phosphatase (EC 3.1.3.2) in serum. Control subjects, patients with benign prostatic hyperplasia, and patients in all four clinical stages of prostatic adenocarcinoma were tested. The upper limit of normal (95%of the population) by the ELISA was 2.0 ..mu..g/L, and by the RIA was 2.2 ..mu..g/L. In prostatic a denocarcinoma stage I (not detectable by digital rectal examination), ELISA was slightly more sensitive than RIA, but sensitivity was still relatively low (20%). As tumor mass increased (stages II through IV), the frequency of increased concentrations of prostatic acid phosphatase in serum also increased. We confirmed this increase in circulating enzyme in some cases of benign prostatic hyperplasia and suggest that this finding is related to either acinar cytolysis or an increase in acini size and number. Although prostate-specific acid phosphatase is not a cancer-specific enzyme, we conclude that its measurement may be of considerable value in monitoring prostatic disease.

Research Organization:
Donald N. Sharp Memorial Community Hospital, San Diego, CA
OSTI ID:
5545324
Journal Information:
Clin. Chem. (Winston-Salem, N.C.); (United States), Vol. 28:1
Country of Publication:
United States
Language:
English